ArticleiScience2026
Potential role of platelet-derived growth factor D in atherosclerotic cardiovascular disease risk.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A considerable residual cardiovascular risk persists despite contemporary therapies, highlighting the urgent need to identify potential targets for atherosclerotic cardiovascular disease (ASCVD) onset and progression. Accumulating evidence suggests that platelet-derived growth factor D (PDGFD) may be involved in the development of ASCVD. Herein, we leveraged 20-year longitudinal data from the Chinese Multi-provincial Cohort Study-Proteomics Project, with up to four repeated PDGFD measurements per participant, to estimate the serum PDGFD-ASCVD association. We then emulated the effectiveness of hypothetical reductions in PDGFD serum levels on ASCVD prevention. Our findings suggest that elevated circulating PDGFD levels are associated with higher ASCVD risk and that hypothetical PDGFD-lowering strategies may be associated with reduced long-term ASCVD risk, with an estimated absolute risk reduction of up to approximately 9% under the most intensive intervention scenario. We anticipate that these findings may motivate further investigation of PDGFD-lowering strategies as a potential approach for ASCVD risk reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.